Market revenue in 2023 | USD 152.5 million |
Market revenue in 2030 | USD 229.9 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III |
Key market players worldwide | Almac Group, Catalent Inc, Waldencast PLC Class A, PCI Technology, Sharp Corp, Thermo Fisher Scientific Inc, PAREXEL, Marken, KLIFO, BioCair |
Phase iii was the largest segment with a revenue share of 53.57% in 2023. Horizon Databook has segmented the UK clinical trial supplies market based on phase i, phase ii, phase iii covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is one of the major hubs for biopharmaceutical companies based in Europe, such as GlaxoSmithKline plc, AstraZeneca, & Novartis, and all the clinical trials being conducted across Europe have some part of their supply chain going through the UK.
Major clinical supplies service players such as DHL, PCI, Alamac, Fisher Clinical, and Catalent have distribution and packaging centers in the UK, which provide services across Europe.
Brexit can have a major impact on small Contract Research Organizations (CROs) and Contract Manufacturing and Packaging Organizations (CMOs and CPOs) based in the UK owing to uncertain regulatory changes related to supply chain.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account